InnoCentive, Inc. Release: Two InnoCentive Solvers Win $40,000 for Devising New Methods to Cost-Effectively Manufacture Tuberculosis Drug Candidate

WALTHAM, MA--(Marketwire - December 03, 2008) - InnoCentive, Inc., the global innovation marketplace, and The Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership dedicated to accelerating the discovery and development of new Tuberculosis (TB) drugs, today announced the conclusion of a Challenge posted last spring that sought methods for accelerating and simplifying the manufacturing process for a promising new TB drug candidate.